Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 12/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120273 | 0.89 | MAPK14 (0.57) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5115765 | 0.87 | MAPK8 (0.62) | MAPK14MAPK8 | |
| SCHEMBL5114375 | 0.85 | MAPK14 (0.58) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL29829634 | 0.83 | MAPK14 (0.69) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL2297482 | 0.83 | MAPK14 (0.69) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5121012 | 0.83 | MAPK14 (0.56) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5107470 | 0.83 | MAPK14 (0.55) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL14039072 | 0.83 | MAPK8 (0.52) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5114115 | 0.81 | MAPK14 (0.48) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL5116393 | 0.81 | MAPK14 (0.56) | MAPK14MAPK8MAPK9MAPK10MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7320987-B2 | 6-Alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320987-B2 | 6-Alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1539755-B1 | 6-ALKOXY-PYRIDO-PYRIMIDINES AS P-38 MAP KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-20070167484-A1 | 6-Alkoxy-pyrido-pyrimidines | GOLDSTEIN DAVID M | 2007-07-19 | — | — | US | disclosed |
| US-20070167484-A1 | 6-Alkoxy-pyrido-pyrimidines | GOLDSTEIN DAVID M | 2007-07-19 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-7196097-B2 | 6-alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060276646-A1 | 6-alkoxy-pyrido-pyrimidines | GOLDSTEIN DAVID M | 2006-12-07 | — | — | US | disclosed |
| US-6965030-B2 | 6-alkoxy-pyrido-pyridine | ROCHE PALO ALTO LLC (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1361880-B1 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| US-20040116698-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN JEFFREY (US) | 2004-06-17 | — | — | US | disclosed |
| US-20040038999-A1 | 6-alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC | 2004-02-26 | — | — | US | disclosed |
| US-6696566-B2 | SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES | SYNTEX (U.S.A.) LLC | 2004-02-24 | — | — | US | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | P2RX6, P2RX1, P2RX7 | MAPK14 4250/4885MAPK8 3523/4885MAPK9 1204/4885 |
| US-20040038999-A1 | 6-alkoxy-pyrido-pyrimidines | CYP2B6, CYP2D6, CNR1 | MAPK14 4498/4885MAPK8 4373/4885MAPK9 4140/4885 |
| US-20060276646-A1 | 6-alkoxy-pyrido-pyrimidines | PDXK, PNPO, CYP2D6 | MAPK14 4426/4885MAPK8 4307/4885MAPK9 3618/4885 |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | MAPK14 64/4885MAPK8 3/4885MAPK9 59/4885 |
| US-20070167484-A1 | 6-Alkoxy-pyrido-pyrimidines | CCNO, PNPO, CYP2B6 | MAPK14 4565/4885MAPK8 4288/4885MAPK9 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.